Ingrid Claverie-Chau
Associate Research Principal, Evidence, Value, and Access
Ingrid is a Market Access Senior Consultant since 2016 at stève consultants, the local French brand of Cytel company. After her pharmacy degree near Paris, she held different internships in hospitals, industries and French Authority of Medicines (ANSM). Then, Ingrid worked for 6 years in the French Authority ANSM and was particularly in charge of efficacy and safety assessment for Marketing Authorization. Then, Ingrid worked +9 years in Market Access Department at stève consultants Company, focusing in the writing of French reimbursement dossier, price/reimbursement strategy in a wide variety of therapeutic areas, with special expertise regarding new reforms such as Early Access and EU-HTA. Global/Local synergies are crucial in EU-HTA. Our extensive knowledge of French HTA expectations enables us to anticipate evidence requirements and bridge EU JCA with French national decision-making by focusing on value-critical evidence.
Related Articles
